Stockscreener 앱 받기
89.08
2.07%
1.81
시간 외 거래:
89.00
-0.08
-0.09%
전일 마감가:
$87.27
열려 있는:
$86.63
하루 거래량:
1.23M
Relative Volume:
0.63
시가총액:
$11.68B
수익:
$982.02M
순이익/손실:
$-416.28M
주가수익비율:
-26.87
EPS:
-3.3148
순현금흐름:
$-233.07M
1주 성능:
+6.02%
1개월 성능:
-16.26%
6개월 성능:
+50.60%
1년 성능:
+92.65%
1일 변동 폭
$84.78
$90.28
1주일 범위
$84.77
$90.28
52주 변동 폭
$36.36
$120.74
가든트헬스 Stock (GH) Company Profile
명칭
Guardant Health Inc
전화
855-698-8887
주소
3100 HANOVER STREET, PALO ALTO
Compare GH vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GH
Guardant Health Inc
|
89.08 | 11.45B | 982.02M | -416.28M | -233.07M | -3.3148 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
가든트헬스 Stock (GH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 재확인 | Canaccord Genuity | Buy |
| 2026-02-17 | 개시 | Robert W. Baird | Outperform |
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-12-02 | 재개 | Morgan Stanley | Overweight |
| 2025-09-25 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2025-09-22 | 재개 | Wells Fargo | Overweight |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-06-28 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-04-24 | 재개 | Craig Hallum | Buy |
| 2023-12-14 | 개시 | Guggenheim | Neutral |
| 2023-12-13 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-13 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-09-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-05-05 | 개시 | UBS | Buy |
| 2023-03-09 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-01-05 | 개시 | Scotiabank | Sector Outperform |
| 2022-11-01 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-10-19 | 개시 | Craig Hallum | Buy |
| 2022-10-06 | 개시 | Stephens | Overweight |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Overweight |
| 2022-04-28 | 재개 | BTIG Research | Buy |
| 2022-02-24 | 재확인 | Canaccord Genuity | Buy |
| 2022-02-24 | 재확인 | Citigroup | Buy |
| 2022-02-24 | 재확인 | Cowen | Outperform |
| 2022-02-24 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-24 | 재확인 | SVB Leerink | Outperform |
| 2022-02-24 | 재확인 | Stifel | Buy |
| 2022-02-24 | 재확인 | Wells Fargo | Overweight |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-06-15 | 개시 | Raymond James | Mkt Perform |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Overweight |
| 2021-01-11 | 개시 | Stifel | Buy |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-06-12 | 개시 | BTIG Research | Buy |
| 2020-02-21 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-08-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-04-16 | 개시 | Canaccord Genuity | Buy |
| 2019-04-10 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2019-02-28 | 재확인 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | BofA/Merrill | Neutral |
| 2018-10-29 | 개시 | JP Morgan | Overweight |
| 2018-10-29 | 개시 | William Blair | Outperform |
모두보기
가든트헬스 주식(GH)의 최신 뉴스
Guardant Health Stock Analysis: Price Rise vs. Financial Risks | 2026News and Statistics - IndexBox
(GH) Risk Channels and Responsive Allocation - Stock Traders Daily
Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics - Investing.com
Director at Guardant Health (GH) receives 232 shares via RSUs - Stock Titan
Guardant Health (NASDAQ: GH) Form 144 shows proposed insider sale of shares - Stock Titan
Guardant Health to Present 28 Abstracts Highlighting Advances in Tumor Typing, Therapy Selection and Expanded Utility of Multiomic Tissue and Liquid Biopsy Testing at AACR 2026 - BioSpace
Multiple analysts lift Guardant Health, Inc. (GH) targets on screening and data growth - MSN
Why Guardant Health’s (GH) 2026 Screening Story Reinforced Piper Sandler’s Bullish View - Yahoo Finance UK
Blood tests flag new primary cancers and actionable results in AACR data - Stock Titan
Guardant Health (GH) Co-CEO logs RSU grants, tax withholding and trust share transfer - Stock Titan
Guardant Health (GH) Co-CEO receives RSUs and shifts shares to trust - Stock Titan
Guardant Health (NASDAQ:GH) CFO Sells $261,120.00 in Stock - MarketBeat
Guardant Health (GH) director acquires 249 shares via RSU vesting - Stock Titan
Guardant Health (NASDAQ: GH) CLO gains stock through RSU vesting - Stock Titan
Guardant Health (GH) CIO exercises RSUs and PBRSUs; 6,839 shares withheld for taxes - Stock Titan
Guardant Health (GH) CCO gains shares through RSU vesting and tax withholding - Stock Titan
Guardant Health (GH) CMO exercises RSUs; shares withheld to cover taxes - Stock Titan
Guardant Health (GH) CTO exercises 10,714 PSUs; 5,759 shares withheld for taxes - Stock Titan
Guardant Health (GH) CFO sells shares and reports RSU vesting - Stock Titan
Survey Supports Blood Tests for Colorectal Cancer Screening - CUREtoday.com
Here’s Why Artisan Small Cap Fund Bets on Guardant Health (GH) - Insider Monkey
Guardant Health launches Shield Multi-Cancer Detection Test in APAC market - BioSpectrum Asia
Oncology Molecular Diagnostics Market Growth 2026 | NGS, PCR - openPR.com
Guardant Health Touts Quest Deal for Shield, Guardant360 Growth and FDA Milestones at Leerink Conference - MarketBeat
Algert Global LLC Raises Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health Touts Hypergrowth in Guardant360, Reveal MRD and Shield CRC at Barclays Conference - MarketBeat
Singapore's Guardant Health launches Shield Multi-Cancer Detection (MCD) Test in APAC market - BioSpectrum Asia
[144] Guardant Health, Inc. SEC Filing - Stock Titan
Guardant Health launches multi-cancer blood test in Asia through Manulife partnership - Mugglehead Magazine
Guardant Health, Harris Poll Survey Shows 92% of Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered - National Today
Guardant Health, Inc. $GH Shares Bought by Iron Triangle Partners LP - MarketBeat
Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership - Yahoo Finance
HighVista Strategies LLC Acquires 36,318 Shares of Guardant Health, Inc. $GH - MarketBeat
Fred Alger Management LLC Has $39.89 Million Holdings in Guardant Health, Inc. $GH - MarketBeat
Guardant Health, Inc. $GH Shares Purchased by First Light Asset Management LLC - MarketBeat
Guardant Health Shares Bought by Aquatic Capital Management - National Today
Guardant Health, Inc. $GH Shares Bought by Aquatic Capital Management LLC - MarketBeat
Is Guardant Health’s (GH) Shield Tour Redefining Its Competitive Moat in Cancer Screening? - simplywall.st
Colon cancer awareness drives conversation at Pennzoil 400 - ktnv.com
Manulife Announces Exclusive Partnership with Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia - The Manila Times
Pennzoil 400 crowds draw colorectal cancer screening bus to Las Vegas Motor Speedway - KSNV
Cinctive Capital Management LP Buys Stake in Guardant Health - National Today
Eventide Asset Management LLC Lowers Holdings in Guardant Health, Inc. $GH - MarketBeat
Assessing Guardant Health (GH) Valuation As Shield Screening Momentum Builds With FDA Approval And Nationwide Tour - Yahoo Finance
Cinctive Capital Management LP Buys Shares of 121,130 Guardant Health, Inc. $GH - MarketBeat
Shield Progress Draws Attention To Guardant Health’s Valuation And Risks - Yahoo Finance
Guardant Health (GH) Valuation Check As Shield Across America Expands Colorectal Cancer Screening Reach - simplywall.st
Meridiem Capital Partners LP Cuts Stock Holdings in Guardant Health, Inc. $GH - MarketBeat
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings - The Motley Fool
Liquid Biopsy Market to Reach US$28.20 Billion by 2033 at 12.8% - openPR.com
New Guardant Health/Harris Poll Survey Shows 92% of All Eligible Americans Believe Colorectal Cancer Blood Tests Should be Accessible and Covered Similar to Medicare - WFMZ.com
가든트헬스 (GH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.50%
자본화:
|
볼륨(24시간):